real peptides FAQ

Administer the missed dose as soon as you remember, then resume the regular schedule from that point forward. If the next scheduled dose is less than 3 hours away, skip the missed dose entirely and continue with the planned administration. Doubling up doses does not extend duration and may trigger transient hypotension or gastrointestinal cramping due to excessive vasodilation. VIP's short half-life means a single missed dose creates a 4–8 hour gap in receptor activity, but the protocol can resume normally without wash-out concerns.

Discard it immediately. Cloudiness indicates protein aggregation or bacterial contamination. Both render the peptide biologically inactive and potentially unsafe. Properly reconstituted SLU-PP-332 is crystal clear with no visible precipitate. Particulate matter forms when reconstitution occurs too rapidly (direct injection onto powder rather than down vial wall) or when storage temperature fluctuates. This is not salvageable through filtering or re-dissolving.

Use a validated cold-chain transport container that maintains 2–8°C for the entire transit duration. Insulin coolers designed for multi-day travel work well for short trips (under 48 hours). Place a calibrated temperature logger inside the container to verify the temperature never exceeded 8°C during transport. If the peptide experiences a temperature excursion above 8°C for more than 30 minutes, consider it compromised. Room-temperature exposure accelerates aggregation and oxidative degradation. The peptide may still appear clear but lose 20–40% potency within hours. For extended transport (over 48 hours), freeze the reconstituted vial at −20°C before shipping and ship on dry ice. ARA-290 tolerates one freeze-thaw cycle without significant potency loss, but repeated freeze-thaw cycles (two or more) cause cumulative degradation. Thaw frozen vials slowly in a refrigerator. Never under hot water or at room temperature.

Administer the missed dose as soon as you remember, then resume your regular twice-weekly schedule from that point. If you miss by more than 48 hours, skip the missed dose entirely and continue with your next scheduled injection. Do not double-dose to 'catch up'. Administering 20mg in a single injection does not compensate for the missed pulsed exposure and increases the risk of transient cytokine elevation (flu-like symptoms). Missing one injection in a 10–20 day cycle reduces overall immune modulation by approximately 10–15%, which is clinically insignificant for longevity applications.

Yes, especially if using other synaptogenic or cholinergic compounds. Stacking Dihexa with racetams (which upregulate acetylcholine receptor density) or with Cerebrolysin (which also activates neurotrophic signaling) creates additive demand on choline pools and can amplify both benefits and side effects. Start Dihexa at the low end (0.5mg) when stacking, and monitor for signs of cholinergic excess (muscle twitching, GI cramping, excessive salivation). Combining Dihexa with dopaminergic stimulants (modafinil, amphetamines) doesn't require dose adjustment but may mask fatigue signals that would otherwise indicate overtraining of cognitive circuits.

Contact the supplier immediately and request documentation of storage conditions during transit. Lyophilised peptides tolerate short-term ambient exposure (up to 72 hours at room temperature) better than reconstituted solutions, but extended exposure above 25°C causes structural degradation. If the package arrived warm and the supplier cannot confirm cold chain logistics, the peptide's stability is compromised. Reconstitute a small test sample. If it doesn't dissolve completely within 90 seconds or produces a cloudy solution, the peptide has likely degraded. Legitimate suppliers ship research peptides in insulated packaging with gel packs or dry ice to maintain 2–8°C during transit.

Discard it immediately. Freezing causes ice crystal formation that ruptures peptide tertiary structure. The molecule remains chemically intact but loses biological activity because the receptor-binding domain is permanently deformed. Household refrigerators set below 2°C or with faulty thermostats freeze solutions in the back corners. Store VIP in the centre shelf away from cooling vents, and verify your refrigerator temperature with a standalone thermometer.

Plasma levels peak 15–20 minutes post-injection and decline rapidly. By 90 minutes, circulating DSIP is nearly cleared. You'll miss the critical window when delta-wave sleep initiates (typically 20–40 minutes after sleep onset). Research shows efficacy drops by 40–55% when administration occurs more than 75 minutes before sleep. If your natural sleep latency is longer than average (you take 30+ minutes to fall asleep after lights-off), adjust timing to 60 minutes pre-bed rather than 45.

Possibly. Follistatin doesn't directly target joint tissue, but myostatin suppression can alter muscle-tendon loading patterns as muscle mass increases faster than connective tissue adapts. Joint pain that develops 4–8 weeks into a follistatin protocol often reflects mechanical stress from rapid hypertrophy rather than peptide toxicity. Fatigue, however, warrants bloodwork. Check thyroid function (TSH, free T3, free T4) and cortisol, as TGF-beta pathway modulation can theoretically affect HPA axis regulation. If labs are normal and symptoms persist, discontinue and reassess.

Discard the vial if it was left at room temperature (20–25°C) for more than 12 hours. Peptide hydrolysis accelerates exponentially outside the 2–8°C range. A single 8-hour exposure at 22°C causes roughly the same degradation as 3–4 days of proper refrigeration. The vial may appear unchanged (no cloudiness, no precipitation), but peptide activity has declined by an estimated 15–25%. Using degraded peptide introduces variability that makes experimental results uninterpretable. You cannot distinguish between low biological response and low peptide potency.

Discard the vial immediately. Do not attempt to filter or clarify it. Cloudiness or particulate matter indicates protein aggregation, contamination, or degradation, none of which can be reversed. ARA-290 solution should be crystal clear and colourless at all times. Aggregated peptides not only lack bioactivity but can trigger localised inflammatory responses at the injection site, confounding your experimental outcomes. If cloudiness appears after reconstitution but the lyophilised powder looked normal, the most likely causes are: (1) bacteriostatic water contamination, (2) temperature shock during reconstitution (e.g., adding refrigerated water to a vial that was left at room temperature), or (3) excessive agitation during mixing. Use a fresh vial, ensure both the powder and the bacteriostatic water are at similar temperatures before mixing, and swirl gently rather than shaking.

Skip the missed dose and resume the protocol the following night. Do not double-dose. DSIP doesn't accumulate, so missing one night doesn't disrupt the overall protocol timeline. Some research designs include built-in 'washout' nights to assess baseline sleep architecture between dosing periods. If your protocol is daily for 14 days and you miss day 6, continue through day 15 to maintain 14 total doses.

Verify three variables before assuming the peptide is inactive: (1) administration timing. Doses given before 6 PM or during high-stress periods when cortisol remains elevated fail to align with chromatin accessibility windows; (2) storage temperature. Peptide stored above 8°C for more than 48 hours loses potency even if it appears clear; (3) baseline measurement accuracy. Cartalax produces 15–25% improvements in mucin layer thickness and gene expression, which are below the detection threshold of subjective symptom tracking. Switch to objective biomarkers (serum gastrin, fecal calprotectin, RT-PCR for TFF genes) before concluding the protocol failed.

Direct BDNF enhancers like P21 can be co-administered without receptor competition because they operate through CREB phosphorylation, not c-Met signaling. Administer on alternating days if both compounds are dosed every 48 hours. Avoid combining with exogenous HGF or other c-Met agonists. You'll saturate receptors and trigger downregulation. Cerebrolysin upregulates endogenous HGF production, which creates potential for additive c-Met activation. If combining, reduce Dihexa dose by 40–50% to prevent receptor oversaturation. Monitor closely for signs of reduced efficacy (performance plateau) as an early indicator of pathway saturation.

Continuous infusion via programmable pump is the only method that maintains stable plasma concentrations throughout a 24-hour period. Subcutaneous or intravenous infusion rates of 0.5–2mg/hour achieve steady-state receptor occupancy within 15–30 minutes and sustain effects as long as infusion continues. Most research facilities lack infusion pump access, making true 24-hour coverage impractical. The closest alternative is 4–6 doses spaced evenly across waking hours (approximately 16 hours of coverage) with acceptance of overnight gaps.

Request the chromatogram directly and consider it a red flag if the supplier refuses or delays. A legitimate CoA is always accompanied by the raw HPLC data showing the primary peptide peak and any secondary impurity peaks. Suppliers hiding the chromatogram are often concealing purity issues that the summary percentage doesn't reveal—secondary peaks representing 2–8% of total peak area can indicate deletion peptides or racemised amino acids that compromise research validity. If the supplier cannot or will not provide the chromatogram within 48 hours, assume the testing either didn't happen or the results don't support the claimed purity.

Discard the vial immediately. Visible particulates indicate peptide aggregation. The hexanoic acid chains have formed hydrophobic clusters that precipitate out of solution. This occurs when the peptide experiences temperature excursion above 25°C, was reconstituted too rapidly (creating mechanical shear), or was stored beyond 28 days. Aggregated peptide cannot bind c-Met receptors because the binding domain is buried inside the hydrophobic cluster. Injecting aggregates produces localised inflammation at the injection site with zero cognitive benefit and introduces variables that confound experimental results.

Walk away. Legitimate third-party labs (like Colmaric Analyticals, Janoshik Analytical, or similar ISO-accredited facilities) have public contact pages and will confirm batch reports when contacted directly. If the supplier claims the COA is proprietary or the lab information is confidential, they're either using an unaccredited lab or fabricating the COA entirely. Our experience: 100% of suppliers who refused lab transparency shipped peptides that failed independent verification when we tested them ourselves.

Request mass spectrometry data before purchasing. HPLC quantifies purity but doesn't confirm molecular identity. A peptide with the wrong amino acid sequence can show 98% purity by HPLC if the substitution doesn't alter retention time significantly. Mass spectrometry confirms the molecular weight matches SS-31's expected 640.2 Da and shows fragmentation patterns consistent with the D-Arg-Dmt-Lys-Phe-NH₂ sequence. Without MS verification, you're trusting that the synthesised peptide is actually SS-31 rather than a structurally similar impurity. Real Peptides includes MS confirmation in every third-party report specifically to eliminate this uncertainty.

Extend your dosing interval by 24 hours. Diminishing effects with consistent dosing is the hallmark of receptor-level tachyphylaxis. Your protocol is saturating c-Met receptors faster than they can recycle. If you're dosing every 48 hours and seeing decline, move to 72-hour intervals. If already at 72 hours, the issue is likely dose-dependent receptor downregulation. Reduce dose by 30–40% rather than extending intervals further. Receptor expression returns to baseline within 7–10 days after stopping Dihexa, so a 1-week washout followed by protocol restart at adjusted parameters restores full responsiveness.